Company announces $30 million Series A financing and founding leadership team with expertise in pulmonary drug innovation and track record ...

An Insilico Medicine drug candidate spawned by the company’s artificial intelligence technology now has clinical data showing breathing improvement in patients who have a debilitating lung disorder.

Nalbuphine extended release (ER) significantly reduces cough frequency and severity in patients with idiopathic pulmonary fibrosis (IPF), especially at higher doses, compared with placebo. The trial ...

SAN DIEGO -- Two novel drugs improved lung function in idiopathic pulmonary fibrosis (IPF) in a pair of phase IIa trials, researchers reported here. In an open-label, single-arm trial of 46 patients ...

Even a disease as deadly as idiopathic pulmonary fibrosis (IPF) can start out as just a cough. But as the condition progresses, a person might experience up to 500 respiratory spasms per day.

Researchers have identified a potential new way to treat idiopathic pulmonary fibrosis (IPF), a deadly and currently incurable lung disease that affects more than 3 million people worldwide.

Key Points Interested in Contineum Therapeutics, Inc.? Here are five stocks we like better. Contineum remains focused on PIPE ...

Dublin, March 28, 2017 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "Global Idiopathic Pulmonary Fibrosis (IPF) Pipeline Analysis, 2016" report to their offering. The IPF ...

Researchers reveal critical mechanism behind idiopathic pulmonary fibrosis. Rutgers Health researchers have discovered that networks of misplaced immune cells drive an aggressive lung disease, ...